Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D-cycloserine + behavioral therapy
- Development stage
- Unknown
- Lead developer
- Duke University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
D-cycloserine + behavioral therapy is a combination intervention developed by Duke University for the treatment of tobacco use disorder, specifically targeting light smokers. The pharmacological component, D-cycloserine (DCS), is a small molecule that acts as a partial agonist at the glycine-binding site of the N-methyl-D-aspartate (NMDA) receptor. By modulating NMDA receptor activity, DCS is thought to enhance synaptic plasticity and facilitate the extinction of conditioned responses. In this intervention, DCS is used as an adjunct to behavioral counseling, which includes enhanced cue exposure treatment (CET) and interactive SMS-based support. The goal of this combined approach is to accelerate the extinction of smoking-related cues and improve cessation outcomes. The intervention was evaluated in the Project Q pilot study at Duke University.
- Brand names
- Seromycin
- Other names
- Counseling and active drug intervention-Duke University-tobacco use disorderD-cycloserine + cue exposure therapyProject Q interventionDCS + CETD-cycloserineCycloserine
02
Targets
N-methyl-D-aspartate receptor glycine site (NMDAR glycine site)
Beyond the preview
Go deeper on D-cycloserine + behavioral therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on D-cycloserine + behavioral therapy.